Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.

@article{Clercq2009AnotherTS,
  title={Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.},
  author={Erik de Clercq},
  journal={Medicinal research reviews},
  year={2009},
  volume={29 4},
  pages={611-45}
}
The ten stories told here deal with (i) ribavirin as an inhibitor of IMP dehydrogenase and (ii) ribavirin, in combination with pegylated interferon, as the present "standard of care" for hepatitis C; (iii) S-adenosylhomocysteine hydrolase inhibitors as antiviral agents; (iv) new adamantadine derivatives for the treatment of influenza A virus infections; (v) 5-substituted 2'-deoxyuridines (i.e. IDU, TFT) for the treatment of herpes simplex virus (HSV) infections; (vi) acyclic guanosine analogues… CONTINUE READING
28 Citations
205 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 205 references

Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture

  • RA Heijtink, J Kruining, GA de Wilde, J Balzarini, E De Clercq, SW. Schalm
  • Antimicrob Agents Chemother
  • 1994
Highly Influential
5 Excerpts

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

  • RA Heijtink, GA de Wilde, +5 authors SW. Schalm
  • Antiviral Res
  • 1993
Highly Influential
4 Excerpts

The discovery of antiviral agents: Ten different compounds, ten different stories

  • E. De Clercq
  • Med Res Rev 2008;28:929–953
  • 2008
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…